Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis
Restricted accessReview articleFirst published online October, 2024
Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis
Several studies have shown that vancomycin combined with piperacillin/tazobactam (VPT) increased the risk of acute kidney injury (AKI) compared with other antibiotics in children. However, the epidemiology of VPT-associated AKI in children is unknown.
Objective:
To evaluate the incidence and risk factors of VPT-associated AKI in children.
Data sources:
Literature databases of PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Database, WanFang Database, and China Biology Medicine Disc were searched from inception to November 2023. References of included studies were also manually checked.
Study selection and data extraction:
Two independent reviewers selected studies, extracted data, and quality assessment. Meta-analyses were performed to quantify the incidence and risk factors of VPT-associated AKI in children.
Data synthesis:
Sixteen cohort studies were identified. Overall, the incidence of VPT-associated AKI in children was 24.3% (95% CI: 17.9%-30.6%). The incidence of VPT-associated AKI in critically ill children (26.6%) was higher than that in noncritically ill children (10.9%). Moreover, higher serum vancomycin trough concentration (>15 mg/L), use of vasopressors, combination of nephrotoxins and intensive care unit admission were risk factors for VPT-associated AKI in children (P < 0.05).
Relevance to patient care and clinical practice:
Identifying high-risk groups and determining safer treatments is critical to reducing the incidence of VPT-associated AKI in children.
Conclusions:
The incidence of VPT-associated AKI in children is high, especially in critically ill children. Medication regimens should be personalized based on the presence of individual risk factors. Moreover, renal function was regularly assessed throughout treatment with VPT.
AskenaziDJGriffinRMcGwinGCarloWAmbalavananN.Acute kidney injury is independently associated with mortality in very low birthweight infants: a matched case-control analysis. Pediatr Nephrol. 2009;24(5):991-997. doi:10.1007/s00467-009-1133-x
4.
PlötzFBBoumaABvan WijkJAKneyberMCBökenkampA.Pediatric acute kidney injury in the ICU: an independent evaluation of pRIFLE criteria. Intensive Care Med. 2008;34(9):1713-1717. doi:10.1007/s00134-008-1176-7
5.
GoldsteinSLDevarajanP.Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis. 2008;15(3):278-283. doi:10.1053/j.ackd.2008.04.007
6.
AskenaziDJFeigDIGrahamNMHui-StickleSGoldsteinSL.3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int. 2006;69(1):184-189. doi:10.1038/sj.ki.5000032
7.
BentleyMLCorwinHLDastaJ.Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med. 2010;38(6 suppl):s169-s174. doi:10.1097/CCM.0b013e3181de0c60
8.
PatzerL.Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23(12):2159-2173. doi:10.1007/s00467-007-0721-x
9.
ChanJCWilliamsDMRothKS.Kidney failure in infants and children. Pediatr Rev. 2002;23(2):47-60. doi:10.1542/pir.23-2-47
10.
AndreoliSP.Acute kidney injury in children. Pediatr Nephrol. 2009;24(2):253-263. doi:10.1007/s00467-008-1074-9
11.
Hui-StickleSBrewerEDGoldsteinSL.Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis. 2005;45(1):96-101. doi:10.1053/j.ajkd.2004.09.028
12.
McKamySHernandezEJahngMMoriwakiTDeveikisALeJ.Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158(3):422-426. doi:10.1016/j.jpeds.2010.08.019
13.
SeixasGTAraujoORSilvaDCArduiniRGPetrilliAS.Vancomycin therapeutic targets and nephrotoxicity in critically ill children with cancer. J Pediatr Hematol Oncol. 2016;38(2):e56-e62. doi:10.1097/mph.0000000000000470
14.
LeJNyPCapparelliE, et al. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. J Pediatric Infect Dis Soc. 2015;4(4):e109-e116. doi:10.1093/jpids/piu110
15.
KnodererCANicholsKRLyonKCVeverkaMMWilsonAC.Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?Pediatric Infect Dis Soc. 2014;3(2):127-131. doi:10.1093/jpids/pit076
16.
TotapallyBRMachadoJLeeHParedesARaszynskiA.Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33(6):598-602. doi:10.1002/phar.1259
17.
ZhengHTruongJCarrollFPaiMP.Do formulation differences between the reference listed drug and generic piperacillin-tazobactam impact reconstitution?Antimicrob Agents Chemother. 2015;59(3):1767-1769. doi:10.1128/aac.04563-14
18.
YangHZhangCZhouQWangYChenL.Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS ONE. 2015;10(1):e0116769. doi:10.1371/journal.pone.0116769
19.
LutherMKTimbrookTTCaffreyARDosaDLodiseTPLaPlanteKL.Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12-20. doi:10.1097/ccm.0000000000002769
20.
BurgessLDDrewRH.Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670-676. doi:10.1002/phar.1442
ChenNAleksaKWoodlandCRiederMKorenG.Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006;21(2):160-168. doi:10.1007/s00467-005-2105-4
23.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
24.
StangA.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z
25.
NadigNHuffNGCoxCEFordDW.Coping as a multifaceted construct: associations with psychological outcomes among family members of mechanical ventilation survivors. Crit Care Med. 2016;44(9):1710-1717. doi:10.1097/ccm.0000000000001761
26.
Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1-138. doi:10.1038/kisup.2012.1
27.
Akcan-ArikanAZappitelliMLoftisLLWashburnKKJeffersonLSGoldsteinSL.Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028-1035. doi:10.1038/sj.ki.5002231
28.
BartlettJWGillonJHaleJJimenez-TruqueNBanerjeeR.Incidence of acute kidney injury among infants in the neonatal intensive care unit receiving vancomycin with either piperacillin/tazobactam or cefepime. J Pediatr Pharmacol Ther. 2020;25(6):521-527. doi:10.5863/1551-6776-25.6.521
29.
AlqurashiRBatwaMAlghamdiB, et al. Acute kidney injury in pediatric patients treated with vancomycin and piperacillin-tazobactam versus vancomycin and cefotaxime: a single-center study. Cureus. 2020;12(1):e6805. doi:10.7759/cureus.6805
30.
QuachHTEsbenshadeAJZhaoZBanerjeeR.Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime. Pediatr Blood Cancer. 2019;66(7):e27750. doi:10.1002/pbc.27750
31.
CookKMGillonJGrissoAG, et al. Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study. J Pediatric Infect Dis Soc. 2019;8(3):221-227. doi: 10.1093/jpids/piy030
32.
BuhlingerKMFullerKAFairclothCBWallaceJR.Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients. Am J Health Syst Pharm. 2019;76(16):1204-1210. doi:10.1093/ajhp/zxz125
33.
AhmadAGableBBostJ, et al. Antibiotic-associated acute kidney injury in critically ill children with cardiac disease. Crit Care Med. 2019;47(1supplement 1):2243-2251. doi:10.1097/01.ccm.0000552210.80965.26
34.
Al NuhaitMAbu EsbaLCAl HarbiKAl MesharyMBustamiRT.Acute kidney injury in pediatric treated with vancomycin and piperacillin-tazobactam in tertiary care hospital. Int J Pediatr. 2018;2018:9256528. doi:10.1155/2018/9256528
35.
AbouelkheirMAlsubaieS.Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam. Pediatr Int. 2018;60(2):136-141. doi:10.1111/ped.13463
36.
LeCleirLKPettitRS.Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatr Pulmonol. 2017;52(8):1000-1005. doi:10.1002/ppul.23718
37.
HundeshagenGHerndonDNCapekKD, et al. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care. 2017;21(1):318. doi:10.1186/s13054-017-1899-3
38.
HolsenMRMeaneyCJHassingerABFuscoNM.Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam. Pediatr Crit Care Med. 2017;18(12):e585-e591. doi:10.1097/pcc.0000000000001335
39.
DownesKJCowdenCLaskinBL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatr. 2017;171(12):e173219. doi:10.1001/jamapediatrics.2017.3219
40.
McQueenKEClarkDW.Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients?J Pediatr Pharmacol Ther. 2016;21(4):332-338. doi:10.5863/1551-6776-21.4.332
41.
BurnsANNguyenVSmithMStewartKLaetschTW.Incidence of acute kidney injury in pediatric oncology patients receiving combination therapy with vancomycin and piperacillintazobactam or cefepime. Open Forum Infect Dis. 2016;3(supplement 1):1811. doi:10.1093/ofid/ofw172.1359
42.
GaoXLingJLiZP.Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam. Fudan Univ J Med Sci. 2015;42(6):743-748. doi:10.3969/j.issn.1672-8467.2015.06.009
43.
ShinBSShinSHParkSGKimEKKimHS.Factors associated with acute kidney injury among preterm infants administered vancomycin: a retrospective cohort study. BMC Pediatr. 2023;23(1):296. doi:10.1186/s12887-023-04085-z
44.
ZazuliZOp’t HoogCJPVijverbergSJH, et al. Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. Pediatr Nephrol. 2023;38(2):593-604. doi:10.1007/s00467-022-05632-z
45.
SutherlandSMByrnesJJKothariM, et al. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. Clin J Am Soc Nephrol. 2015;10(4):554-561. doi:10.2215/cjn.01900214
46.
RutterWCBurgessDS.Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. Antimicrob Agents Chemother. 2018;62(7):e00264. doi:10.1128/aac.00264-18
47.
BagshawSMBellomoRDevarajanP, et al. Review article: acute kidney injury in critical illness. Can J Anaesth. 2010;57(11):985-998. doi:10.1007/s12630-010-9375-4
48.
HammondDASmithMNLiCHayesSMLusardiKBookstaverPB.Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666-674. doi:10.1093/cid/ciw811
49.
MolinaKCBarlettaJFHallSTYazdaniCHuangV.The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime. J Intensive Care Med. 2020;35(12):1434-1438. doi:10.1177/0885066619828290
50.
KangSParkJYuYMParkMSHanEChangMJ.Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS ONE. 2019;14(6):e0217908. doi:10.1371/journal.pone.0217908
51.
BlevinsAMLashinskyJNMcCammonCKollefMMicekSJuangP.Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother. 2019;63(5):e02658. doi:10.1128/aac.02658-18
52.
RobertsonADLiCHammondDADickeyTA.Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem. Pharmacotherapy. 2018;38(12):1184-1193. doi:10.1002/phar.2179
53.
KnodererCAGritzmanALNicholsKRWilsonAC.Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy. Ann Pharmacother. 2015;49(10):1113-1119. doi:10.1177/1060028015594190
54.
HazlewoodKABrouseSDPitcherWDHallRG.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Am J Med. 2010;123(2):182e1-182e7. doi:10.1016/j.amjmed.2009.05.031
55.
MeaneyCJHynickaLMTsouklerisMG.Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy. 2014;34(7):653-661. doi:10.1002/phar.1423
56.
GomesDMSmothermanCBirchA, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34(7):662-669. doi:10.1002/phar.1428
57.
ChenCPanKMZouY, et al. Acute kidney injury induced by vancomycin combined with piperacillin/tazobactam among hospitalized children: a systematic review and meta analysis. Clin Med J. 2018;16(1):42-46. doi:10.3969/j.issn.1672-3384.2018.01.010
58.
SchreierDJKashaniKBSakhujaA, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin. Clin Infect Dis. 2019;68(9):1456-1462. doi:10.1093/cid/ciy724
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
